Sensus Healthcare, Inc. (SRTS) is a pioneering medical device company that specializes in non-invasive treatments for both malignant and non-malignant skin conditions, including different types of skin cancer. Their primary focus is on utilizing low-energy X-ray technology to deliver innovative, practical treatment solutions that lead to better patient outcomes and quality of life.
With its headquarters located in Florida, the United States, Sensus Healthcare caters to a diversified global client base, including physicians, hospitals, and medical institutions across the globe. Incorporated in 2010, the company is dedicated to improving the lives of individuals suffering from skin conditions with their cutting-edge medical device solutions.
Sensus Healthcare's flagship product is the SRT-100™. This device is designed to provide safe and effective non-surgical skin cancer treatments. Harnessing the power of Superficial Radiation Therapy (SRT), the SRT-100™ delivers precise, calibrated doses of radiation that only goes skin deep, effectively targeting the disease without causing damage to healthy tissues or structures beneath the skin layer. This revolutionary technology has been recognized for minimizing the risks and discomfort associated with surgical interventions, making it a preferred choice among patients and clinicians.
In addition to the SRT-100™, Sensus Healthcare also offers the SRT-100 Vision™, which integrates advanced imaging features along with the SRT, enhancing accuracy and precision during the treatment process. Moreover, the company's portfolio includes the Sculptura™, a first-of-its-kind robotic intraoperative radiation therapy system.
Sensus Healthcare's innovation in non-invasive skin cancer treatments has put them amongst the leading names in the healthcare industry. However, the company doesn't rest on its laurels; it is constantly engaged in research and development activities to enhance its existing products and explore avenues for new solutions. This enthusiasm for continuous improvement and commitment to patient care explains why Sensus Healthcare, Inc. (SRTS) remains the go-to choice for medical practitioners seeking advanced skin care treatments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sensus Healthcare (NASDAQ:SRTS) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $5.83 against its recent price of $3.12. Despite this positive rating, the company reported weaker-than-expected quarterly results, missing revenue estimates and posting a larger loss per share. Insider buying activity has been noted, with insiders acquiring 120,171 shares recently, while institutional investors hold 25.3% of the stock.
Sensus Healthcare Inc. (NASDAQ: SRTS) has launched "Treat Skin Cancer," a comprehensive public awareness and patient education campaign. This initiative aims to guide individuals through all phases of a non-melanoma skin cancer diagnosis, providing educational resources, treatment comparisons, and decision guides. The platform was created to empower patients with essential information and support their journey from diagnosis to treatment and beyond, especially given that one in five Americans will be diagnosed with skin cancer by age 70.
This article highlights three promising penny stocks with market caps over $50 million: Sensus Healthcare (SRTS), MediciNova (MNOV), and Protalix BioTherapeutics (PLX). It provides a financial overview and growth prospects for each, emphasizing that while penny stocks carry risk, those with strong financials can offer opportunities. The report encourages investors to conduct further due diligence and notes that the information is not financial advice.